Hochschulschrift
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Frankfurt am Main, Johann Wolfgang Goethe-Univ., Diss., 2014
- Keyword
-
Endokrinologie
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Univ.-Bibliothek Frankfurt am Main
- (when)
-
2014
- Creator
- Contributor
-
Ruthardt, Martin
Marschalek, Rolf
- URN
-
urn:nbn:de:hebis:30:3-345187
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Associated
- Rafiei, Anahita
- Ruthardt, Martin
- Marschalek, Rolf
- Univ.-Bibliothek Frankfurt am Main
Time of origin
- 2014
Other Objects (12)
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
The role of ABL/BCR in the leukemogenic potential of BCR/ABL in Philadelphia chromosome positive leukemia
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten